Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer
November 13, 2019 01:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, November 13, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer,...
Bavarian Nordic udnævner Jean-Christophe May til Chief Commercial Officer
November 13, 2019 01:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 13. november 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har udnævnt Jean-Christophe May til Executive Vice President og Chief Commercial Officer (CCO) pr....
Bavarian Nordic fuldfører rekrutteringen til fase 3 lot-consistency-forsøg med frysetørret koppevaccine
November 11, 2019 01:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 11. november 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at rekrutteringen af 1.110 forsøgspersoner til det fuldt finansierede fase 3 lot-consistency forsøg, der skal...
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox Vaccine
November 11, 2019 01:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, November 11, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the completion of enrollment of 1,110 subjects for the fully-funded Phase 3 lot-consistency trial...
Bavarian Nordic meddeler at Janssen har indsendt ansøgning om europæisk markedsføringstilladelse for ebolavaccinen
November 07, 2019 06:03 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 7. november 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag at selskabets partner, Janssen Pharmaceutical Companies of Johnson & Johnson, har indsendt ansøgning til Det...
Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen
November 07, 2019 06:03 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, November 7, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that its partner Janssen Pharmaceutical Companies of Johnson & Johnson have submitted Marketing...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
November 07, 2019 01:54 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, November 7, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
November 07, 2019 01:54 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 7. november 2019 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Bavarian Nordic Announces Interim Results for the First Nine Months of 2019
November 07, 2019 01:44 ET
|
Bavarian Nordic A/S
On track to meet 2019 full year guidance; expects to become profitable on EBITDA in 2020RSV Phase 3 study design now confirmed with FDA; study will initiate in 2021Updates to financial calendar ...
Bavarian Nordic offentliggør delårsregnskab for de første ni måneder af 2019
November 07, 2019 01:44 ET
|
Bavarian Nordic A/S
Fastholder forventningerne til helårsresultatet for 2019; forventer at være EBITDA profitabel i 2020Udformningen af fase 3 forsøget for RSV er nu på plads med FDA; forsøget påbegyndes i...